- Home
- ULH vs ANAB Comparison
ULH vs ANAB Comparison
Compare ULH & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULH
- ANAB
- Stock Information
- Founded
- ULH 1932
- ANAB 2005
- Country
- ULH United States
- ANAB United States
- Employees
- ULH N/A
- ANAB N/A
- Industry
- ULH Trucking Freight/Courier Services
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- ULH Industrials
- ANAB Health Care
- Exchange
- ULH Nasdaq
- ANAB Nasdaq
- Market Cap
- ULH 709.5M
- ANAB 759.5M
- IPO Year
- ULH 2005
- ANAB 2017
- Fundamental
- Price
- ULH $23.31
- ANAB $19.59
- Analyst Decision
- ULH Hold
- ANAB Buy
- Analyst Count
- ULH 1
- ANAB 10
- Target Price
- ULH $29.00
- ANAB $37.75
- AVG Volume (30 Days)
- ULH 71.7K
- ANAB 589.1K
- Earning Date
- ULH 04-24-2025
- ANAB 05-05-2025
- Dividend Yield
- ULH 1.80%
- ANAB N/A
- EPS Growth
- ULH N/A
- ANAB N/A
- EPS
- ULH 3.17
- ANAB N/A
- Revenue
- ULH $1,736,518,000.00
- ANAB $111,872,000.00
- Revenue This Year
- ULH N/A
- ANAB N/A
- Revenue Next Year
- ULH $7.92
- ANAB $44.69
- P/E Ratio
- ULH $7.34
- ANAB N/A
- Revenue Growth
- ULH 1.16
- ANAB 387.20
- 52 Week Low
- ULH $20.60
- ANAB $12.21
- 52 Week High
- ULH $53.29
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- ULH 43.32
- ANAB 48.98
- Support Level
- ULH $21.65
- ANAB $18.51
- Resistance Level
- ULH $23.48
- ANAB $21.52
- Average True Range (ATR)
- ULH 1.37
- ANAB 1.16
- MACD
- ULH -0.01
- ANAB -0.26
- Stochastic Oscillator
- ULH 36.75
- ANAB 26.97
About ULH Universal Logistics Holdings Inc.
Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The company reports into four segments namely trucking, intermodal, company-managed brokerage, and contract logistics. The majority of the revenue is earned from the contract logistics segment.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).